Ep. 109 - What's Next for Novartis? Plus: AACR, Merck KGaA
BioCentury This Week
00:00
Is There a Signal Lid in Nevada?
Lorraine: Is there a signal lid, you think, from nevada and how it's going to priorize oncology? Lorraine: We saw the company restructure in two thousand, 16 ahead of its cartee approval. And they've dropped the president an acology. It just means that it's potentially not as big as a focus.
Transcript
Play full episode
